M. V. Ramana Reddy - Concepedia

Author

M. V. Ramana Reddy

Icahn School of Medicine at Mount Sinai ORCID

Also Known As

M V R Reddy, M V Ramana Reddy, M. Reddy, M. V Ramana Reddy, M. V. R. REDDY, M. V. R. Reddy, M. V. REDDY, M. V. Ramana Reddy, M. Veeranarayana Reddy, M.V. Ramana Reddy

129

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Icahn School of Medicine at Mount Sinai Temple University Onconova Therapeutics (United States)Sri Venkateswara University

About

M. V. Ramana Reddy is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	1.6K
2	Natural Sciences	12	13	591
3	Biochemistry	9	9	386
4	Engineering	5	5	91
5	Health Sciences	2	2	103

M. V. Ramana Reddy

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent Kiranmai Gumireddy, M. V. Ramana Reddy, Stephen C. Cosenza, Cancer Cell MedicinePotent Anticancer AgentAnti-cancer AgentTumor SuppressorPharmacology	2005	366
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling Sai Krishna Athaluri Divakar, Rodrigo Vasquez‐Del Carpio, Kaushik Dutta, Cell Block SignalingSignal TransductionEffector ProteinsSignaling PathwayCell Regulation	2016	259
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance Kiranmai Gumireddy, Stacey J. Baker, Stephen C. Cosenza, Proceedings of the National Academy of Sciences	2005	221
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity Natala Srinivasa Reddy, Muralidhar R. Mallireddigari, Stephen C. Cosenza, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDerivative (Chemistry)Natural SciencesMedicineOrganic Chemistry	2004	164
Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors M. V. Ramana Reddy, Vinay K. Billa, Venkat R. Pallela, Bioorganic & Medicinal Chemistry Medicinal Chemistry-3-Trifluoromethyl-5-indolyl PyrazolinesPharmaceutical ScienceBiochemistryMedicine	2008	113
Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (<i>E</i>)-2-{2-Methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure–Activity Relationship, and Biological Activity M. V. Ramana Reddy, V. Padmavathi, Muralidhar R. Mallireddigari, Journal of Medicinal Chemistry Structure–activity RelationshipPharmaceutical ScienceCyclin D ProteinsOn 01910.NaHeterocycle Chemistry	2011	94
Radiation Protection by a New Chemical Entity, Ex-Rad™: Efficacy and Mechanisms Sanchita Ghosh, Michael W. Perkins, Kevin P. Hieber, Radiation Research	2009	75
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells Anil Prasad, I-W Park, H. Allen, Oncogene HeterocyclicBiochemistryStyryl SulfonylCyclin D1Inhibit Translation	2009	73
Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7x</b>) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5) M. V. Ramana Reddy, Balireddy Akula, Stephen C. Cosenza, Journal of Medicinal Chemistry	2014	70
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1 Natala Srinivasa Reddy, Kiranmai Gumireddy, Muralidhar R. Mallireddigari, Bioorganic & Medicinal Chemistry Novel Coumarin-3-Breast OncologyMedicineCancer GrowthBreast Cancer	2005	60

Page 1